Ami Organics needs to prove its case among a wide menu of options
Besides, the pandemic-sparked rally in the pharma-API players has played out with valuations rationalising now.
Synopsis
Ami Organics has developed and commercialised 450 intermediates for active ingredients in 17 key therapeutic areas, and supplies to 150 companies in India and abroad. From the IPO proceeds, Rs 140 crore is to be used to repay debt and ₹90 crore towards funding capital expenditure.
ET Intelligence Group: Surat-based manufacturer of intermediates (raw materials for the bulk drug industry) and speciality chemicals Ami Organics is the latest from the industry to make an initial public offering. The Rs 570 crore IPO comprises fresh shares and an offer for sale by existing investors.Ami Organics has developed and commercialised 450 intermediates for active ingredients in 17 key therapeutic areas, and supplies to 150 companies
Get Unlimited Access to The Economic Times
